The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer's Disease (AD)

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Sep 25

PMID 31547024

Citations 31

Authors

Barbara Mroczko

Magdalena Groblewska

Ala Litman-Zawadzka

Affiliations

Soon will be listed here.

Abstract

Although the causative role of the accumulation of amyloid β 1-42 (Aβ42) deposits in the pathogenesis of Alzheimer's disease (AD) has been under debate for many years, it is supposed that the toxicity soluble oligomers of Tau protein (TauOs) might be also the pathogenic factor acting on the initial stages of this disease. Therefore, we performed a thorough search for literature pertaining to our investigation via the MEDLINE/PubMed database. It was shown that soluble TauOs, especially granular forms, may be the most toxic form of this protein. Hyperphosphorylated TauOs can reduce the number of synapses by missorting into axonal compartments of neurons other than axon. Furthermore, soluble TauOs may be also responsible for seeding Tau pathology within AD brains, with probable link to AβOs toxicity. Additionally, the concentrations of TauOs in the cerebrospinal fluid (CSF) and plasma of AD patients were higher than in non-demented controls, and revealed a negative correlation with mini-mental state examination (MMSE) scores. It was postulated that adding the measurements of TauOs to the panel of CSF biomarkers could improve the diagnosis of AD.

Citing Articles

Meroterpenoids from Terrestrial and Marine Fungi: Promising Agents for Neurodegenerative Disorders-An Updated Review.

Dimitrova D, Dimitrova S, Kehayova G, Dragomanova S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996817 PMC: 11854780. DOI: 10.3390/cimb47020096.

Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials.

Cai W, Zhang H, Wu Y, Yao Y, Zhang J Front Aging Neurosci. 2025; 16:1465871.

PMID: 39945003 PMC: 11814219. DOI: 10.3389/fnagi.2024.1465871.

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy.

Li Y, Fu Q, Guo M, Du Y, Chen Y, Cheng Y Transl Psychiatry. 2024; 14(1):367.

PMID: 39256358 PMC: 11387755. DOI: 10.1038/s41398-024-03075-8.

Clinical Application of Blood Biomarkers in Neurodegenerative Diseases-Present and Future Perspectives.

Krawczuk D, Kulczynska-Przybik A, Mroczko B Int J Mol Sci. 2024; 25(15).

PMID: 39125699 PMC: 11311320. DOI: 10.3390/ijms25158132.

Passive Anti-Amyloid Beta Immunotherapies in Alzheimer's Disease: From Mechanisms to Therapeutic Impact.

Schreiner T, Croitoru C, Hodorog D, Cuciureanu D Biomedicines. 2024; 12(5).

PMID: 38791059 PMC: 11117736. DOI: 10.3390/biomedicines12051096.

References

Dovidchenko N, Leonova E, Galzitskaya O . Mechanisms of amyloid fibril formation. Biochemistry (Mosc). 2015; 79(13):1515-27. DOI: 10.1134/S0006297914130057. View

Huvent I, Kamah A, Cantrelle F, Barois N, Slomianny C, Smet-Nocca C . A functional fragment of Tau forms fibers without the need for an intermolecular cysteine bridge. Biochem Biophys Res Commun. 2014; 445(2):299-303. DOI: 10.1016/j.bbrc.2014.01.161. View

Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R . Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Ann Clin Transl Neurol. 2017; 4(4):226-235. PMC: 5376754. DOI: 10.1002/acn3.382. View

Prusiner S . Biology and genetics of prions causing neurodegeneration. Annu Rev Genet. 2013; 47:601-23. PMC: 4010318. DOI: 10.1146/annurev-genet-110711-155524. View

Mroczko B, Groblewska M, Litman-Zawadzka A, Kornhuber J, Lewczuk P . Amyloid β oligomers (AβOs) in Alzheimer's disease. J Neural Transm (Vienna). 2017; 125(2):177-191. DOI: 10.1007/s00702-017-1820-x. View

Ohm T, Meske V . Cholesterol, statins and tau. Acta Neurol Scand Suppl. 2006; 185:93-101. DOI: 10.1111/j.1600-0404.2006.00692.x. View

MacLea K . What Makes a Prion: Infectious Proteins From Animals to Yeast. Int Rev Cell Mol Biol. 2017; 329:227-276. DOI: 10.1016/bs.ircmb.2016.08.012. View

Avila J, de Barreda E, Pallas-Bazarra N, Hernandez F . Tau and neuron aging. Aging Dis. 2013; 4(1):23-8. PMC: 3570138. View

Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow E . Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999; 38(12):3549-58. DOI: 10.1021/bi981874p. View

10.

SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M . Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309(5733):476-81. PMC: 1574647. DOI: 10.1126/science.1113694. View

11.

Myers A, Pittman A, Zhao A, Rohrer K, Kaleem M, Marlowe L . The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2006; 25(3):561-70. DOI: 10.1016/j.nbd.2006.10.018. View

12.

Soeda Y, Yoshikawa M, Almeida O, Sumioka A, Maeda S, Osada H . Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nat Commun. 2015; 6:10216. PMC: 4703892. DOI: 10.1038/ncomms10216. View

13.

Lansbury Jr P . Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A. 1999; 96(7):3342-4. PMC: 34271. DOI: 10.1073/pnas.96.7.3342. View

14.

Guo T, Noble W, Hanger D . Roles of tau protein in health and disease. Acta Neuropathol. 2017; 133(5):665-704. PMC: 5390006. DOI: 10.1007/s00401-017-1707-9. View

15.

Soto C, Estrada L, Castilla J . Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci. 2006; 31(3):150-5. DOI: 10.1016/j.tibs.2006.01.002. View

16.

Toyama B, Weissman J . Amyloid structure: conformational diversity and consequences. Annu Rev Biochem. 2011; 80:557-85. PMC: 3817101. DOI: 10.1146/annurev-biochem-090908-120656. View

17.

Beach T, Wilson J, Sue L, Newell A, Poston M, Cisneros R . Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 2006; 113(1):13-21. DOI: 10.1007/s00401-006-0136-y. View

18.

Gheyara A, Ponnusamy R, Djukic B, Craft R, Ho K, Guo W . Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann Neurol. 2014; 76(3):443-56. PMC: 4338764. DOI: 10.1002/ana.24230. View

19.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

20.

De Felice F, Lourenco M, Ferreira S . How does brain insulin resistance develop in Alzheimer's disease?. Alzheimers Dement. 2014; 10(1 Suppl):S26-32. DOI: 10.1016/j.jalz.2013.12.004. View